drugset / Trial / NCT07525375

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

NCT07525375

Phase 2 Recruiting 69 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.

Timeline

Start
2026-04-14
Primary completion
2029-05-23
Completion
2029-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown Inhaled
Background Budesonide and Formoterol Fumarate Unknown Inhaled

Indications